Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Just saw that Todd Bazemore got promoted from interim CEO to the full CEO role at KALA BIO, and honestly his background is pretty impressive. The guy's been with the company since 2017, started as COO and then took over as interim CEO back in February. Now he's officially got the top job plus a board seat.
What caught my eye is that Bazemore has like 30+ years in the pharma game - we're talking everything from ultra-rare orphan diseases to mainstream treatments. Before KALA, he was running U.S. operations at Santhera, spent time at Dyax before Shire acquired it, and before that was at Sunovion where he apparently launched 7 new products over 11 years. That's the kind of track record you don't see every day.
So Todd Bazemore going from interim to permanent CEO - feels like the board was pretty confident he was the right call. Curious to see what direction he takes the company from here, especially with all that commercial and operational experience he's bringing to the role.